{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["berberrubine", "hepatotoxicity", "metabolic activation", "protein modification"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "33122887", "DateCompleted": {"Year": "2021", "Month": "08", "Day": "24"}, "DateRevised": {"Year": "2022", "Month": "04", "Day": "17"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "10", "Day": "22"}], "Language": ["eng"], "ELocationID": ["10.2147/DDDT.S274627"], "Journal": {"ISSN": "1177-8881", "JournalIssue": {"Volume": "14", "PubDate": {"Year": "2020"}}, "Title": "Drug design, development and therapy", "ISOAbbreviation": "Drug Des Devel Ther"}, "ArticleTitle": "Metabolic Activation and Covalent Protein Binding of Berberrubine: Insight into the Underlying Mechanism Related to Its Hepatotoxicity.", "Pagination": {"StartPage": "4423", "EndPage": "4438", "MedlinePgn": "4423-4438"}, "Abstract": {"AbstractText": ["Berberrubine (BRB), an isoquinoline alkaloid, is a major constituent of medicinal plants <i>Coptis chinensis</i> Franch or <i>Phellodendron chinense</i> Schneid. BRB exhibits various pharmacological activities, whereas exposure to BRB may cause toxicity in experimental animals.", "In this study, we thoroughly investigated the liver injury induced by BRB in mice and rats. To explore the underlying mechanism, a study of the metabolic activation of BRB was conducted. Furthermore, covalent modifications of cysteine residues of proteins were observed in liver homogenate samples of animals after exposure to BRB, by application of an exhaustive proteolytic digestion method.", "It was demonstrated that BRB-induced hepatotoxicities in a time- and dose-dependent manner, based on the biochemical parameters ALT and AST. H&E stained histopathological examination showed the occurrence of obvious edema in liver of mice after intraperitoneal (i.p.) administration of BRB at a single dose of 100 mg/kg. Slight hepatotoxicity was also observed in rats given the same doses of BRB after six weeks of gavage. As a result, four GSH adducts derived from reactive metabolites of BRB were detected in microsomal incubations with BRB fortified with GSH as a trapping agent. Moreover, four cys-based adducts derived from reaction of electrophilic metabolites of BBR with proteins were found in livers.", "These results suggested that the formation of protein adducts originating from metabolic activation of BRB could be a crucial factor of the mechanism of BRB-induced toxicities."], "CopyrightInformation": "\u00a9 2020 Wang et al."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, People's Republic of China."}], "LastName": "Wang", "ForeName": "Kai", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, People's Republic of China."}], "LastName": "Rao", "ForeName": "Jinqiu", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, People's Republic of China."}], "LastName": "Zhang", "ForeName": "Tingting", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, People's Republic of China."}], "LastName": "Gao", "ForeName": "Qing", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Component-based Chinese Medicine,Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China."}], "LastName": "Zhang", "ForeName": "Jichao", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Component-based Chinese Medicine,Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China."}], "LastName": "Guang", "ForeName": "Chenxi", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Component-based Chinese Medicine,Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China."}], "LastName": "Ding", "ForeName": "Liqin", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, People's Republic of China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Component-based Chinese Medicine,Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China."}], "LastName": "Qiu", "ForeName": "Feng", "Initials": "F"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Drug Des Devel Ther", "NlmUniqueID": "101475745", "ISSNLinking": "1177-8881"}, "ChemicalList": [{"RegistryNumber": "0I8Y3P32UF", "NameOfSubstance": "Berberine"}, {"RegistryNumber": "15401-69-1", "NameOfSubstance": "berberrubine"}], "MeshHeadingList": [{"QualifierName": ["drug effects"], "DescriptorName": "Activation, Metabolic"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["analogs & derivatives", "blood", "metabolism", "toxicity"], "DescriptorName": "Berberine"}, {"QualifierName": ["metabolism", "pathology"], "DescriptorName": "Chemical and Drug Induced Liver Injury"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": ["drug effects", "metabolism", "pathology"], "DescriptorName": "Liver"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred Strains"}, {"QualifierName": ["chemistry", "metabolism"], "DescriptorName": "Microsomes, Liver"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Sprague-Dawley"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}], "CoiStatement": "The authors report no conflicts of interest in this work."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Dunnick JK, Singh B, Nyska A, et al. Investigating the potential for toxicity from long-term use of the herbal products, goldenseal and milk thistle. Toxicol Pathol. 2011;39(2):398\u2013409. doi:10.1177/0192623310394211", "ArticleIdList": ["10.1177/0192623310394211", "21300790"]}, {"Citation": "Blowey DL. Nephrotoxicity of over-the-counter analgesics, natural medicines, and illicit drugs. Adolesc Med Clin. 2005;16(1):31\u201343. doi:10.1016/j.admecli.2004.10.001", "ArticleIdList": ["10.1016/j.admecli.2004.10.001", "15844382"]}, {"Citation": "Perazella MA. Pharmacology behind common drug nephrotoxicities. Clin J Am Soc Nephrol. 2018;13:1897\u20131908.", "ArticleIdList": ["PMC6302342", "29622670"]}, {"Citation": "Randy L, Mark A. Aristolochic acid nephropathy: epidemiology, clinical presentation and treatment. Drug Saf. 2015;38(1):55\u201364. doi:10.1007/s40264-014-0244-x", "ArticleIdList": ["10.1007/s40264-014-0244-x", "25446374"]}, {"Citation": "Debelle DF, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: A worldwide problem. Kidney Int. 2008;74(2):158\u2013169. doi:10.1038/ki.2008.129", "ArticleIdList": ["10.1038/ki.2008.129", "18418355"]}, {"Citation": "Jadot I, Decl\u00e8ves AE, Nortier J, et al. An integrated view of aristolochic acid nephropathy: update of the literature. Int J Mol Sci. 2017;18(2):297. doi:10.3390/ijms18020297", "ArticleIdList": ["10.3390/ijms18020297", "PMC5343833", "28146082"]}, {"Citation": "Bastek H, Zubel Z, Stemme K, et al. Comparison of aristolochic acid I derived DNA adduct levels in human renal toxicity models. Toxicology. 2019;420:29\u201338. doi:10.1016/j.tox.2019.03.013", "ArticleIdList": ["10.1016/j.tox.2019.03.013", "30940547"]}, {"Citation": "Priestap HA, Santos CD, Quirk JM. Identification of a reduction product of aristolochic acid: implications for the metabolic activation of carcinogenic aristolochic acid. J Nat Prod. 2010;73(12):1979\u20131986. doi:10.1021/np100296y", "ArticleIdList": ["10.1021/np100296y", "PMC3040066", "21141875"]}, {"Citation": "Li WW, Lin DG, Gao HY, et al. Metabolic activation of furan moiety makes Diosbulbin B hepatotoxic. Arch Toxicol. 2016;90(4):863\u2013872. doi:10.1007/s00204-015-1495-8", "ArticleIdList": ["10.1007/s00204-015-1495-8", "25851819"]}, {"Citation": "Wang JM, Ji LL, Liu H, et al. Study of the hepatotoxicity induced by Dioscoreabulbifera L. rhizome in mice. Biosci Trends. 2010;4:79\u201385.", "ArticleIdList": ["20448345"]}, {"Citation": "Lin DG, Li CY, Peng Y, et al. Cytochrome P450\u2013mediated metabolic activation of Diosbulbin B. Drug Metab Dispos. 2014;42(10):1727\u20131736. doi:10.1124/dmd.114.059261", "ArticleIdList": ["10.1124/dmd.114.059261", "25024403"]}, {"Citation": "Lin DJ, Li WW, Peng Y, et al. Role of metabolic activation in 8-Epidiosbulbin E acetate-induced liver injury: mechanism of action of the hepatotoxic furanoid. Chem Res Toxicol. 2016;29(3):359\u2013366. doi:10.1021/acs.chemrestox.5b00501", "ArticleIdList": ["10.1021/acs.chemrestox.5b00501", "26886724"]}, {"Citation": "Wang K, Lin DG, Guo XC, et al. Chemical identity of interaction of protein with reactive metabolite of Diosbulbin B in vitro and in vivo. Toxins. 2017;14(8):249.", "ArticleIdList": ["PMC5577583", "28805726"]}, {"Citation": "Zhou SF, Xue CC, Wang GG, Wang G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab. 2007;8(6):526\u2013553. doi:10.2174/138920007781368863", "ArticleIdList": ["10.2174/138920007781368863", "17691916"]}, {"Citation": "Tripathi AN, Chauhan L, Thankacha PP, et al. Quantum chemical and nuclear magnetic resonance spectral studies on molecular properties and electronic structure of berberine and berberrubine. Magn. Reson. Chem. 2007;45(8):647\u2013655. doi:10.1002/mrc.2019", "ArticleIdList": ["10.1002/mrc.2019", "17559166"]}, {"Citation": "Wang K, Feng XC, Chai LW, et al. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev. 2017;49(2):139\u2013157. doi:10.1080/03602532.2017.1306544", "ArticleIdList": ["10.1080/03602532.2017.1306544", "28290706"]}, {"Citation": "Chen ML, Xian YF, Lp SU, et al. Chemical and biological differentiation of Cortex Phellodendri Chinensis and Cortex Phellodendri Amurensis. Planta Med. 2010;76(14):1530\u20131535. doi:10.1055/s-0030-1249774", "ArticleIdList": ["10.1055/s-0030-1249774", "20354951"]}, {"Citation": "Gilca M, Gaman L, Panait E, et al. Chelidonium majus-an integrative review: traditional knowledge versus mod-ern findings. Forsch Komplementmed. 2010;17(5):241\u2013248. doi:10.1159/000321397", "ArticleIdList": ["10.1159/000321397", "20980763"]}, {"Citation": "Zhou Y, Cao SJ, Wang Y, et al. Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells. Fitoterapia. 2014;92:230\u2013237. doi:10.1016/j.fitote.2013.11.010", "ArticleIdList": ["10.1016/j.fitote.2013.11.010", "24321576"]}, {"Citation": "Hu JP, Takahashi NT, Yamada T. Coptidis rhizoma inhibits growth and pro-teases of oralbacteria. Oral Dis. 2000;6(5):297\u2013302. doi:10.1111/j.1601-0825.2000.tb00142.x", "ArticleIdList": ["10.1111/j.1601-0825.2000.tb00142.x", "11002412"]}, {"Citation": "Wright CW, Marshall SJ, Russell PF, et al. In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids. J Nat Prod. 2000;63(12):1638\u20131640. doi:10.1021/np000144r", "ArticleIdList": ["10.1021/np000144r", "11141105"]}, {"Citation": "Baird AW, Taylor CT, Brayden DJ. Non-antibiotic anti-diarrhoeal drugs: factors affecting oral bioavailability of berberine and loperamide in intestinal Tissue.Adv. Drug Deliv Rev. 1997;23(1\u20133):111\u2013120. doi:10.1016/S0169-409X(96)00429-2", "ArticleIdList": ["10.1016/S0169-409X(96)00429-2"]}, {"Citation": "Chen GR, Xu YB, Jing J, et al. The anti-sepsis activity of the components of Huanglian Jiedu Decoction with high lipid A-binding affinity[J]. Int Immunopharmacol. 2017;46:87\u201396. doi:10.1016/j.intimp.2017.02.025", "ArticleIdList": ["10.1016/j.intimp.2017.02.025", "28278436"]}, {"Citation": "Ma HL, Liu Y, Mai X, et al. Identification of the constituents and metabolites in rat plasma after oral administration of HuanglianShangqing pills by ultra high-performance liquid chromatography/quadrupole time-of-flight mass spectrometry[J]. J Pharm Biomed Anal. 2016;125:194\u2013204. doi:10.1016/j.jpba.2016.03.038", "ArticleIdList": ["10.1016/j.jpba.2016.03.038", "27031575"]}, {"Citation": "Huang WY, Dong H. Coptidis Rhizoma-Contained Traditional Formulae for Insomnia: A Potential to Prevent Diabetes?[J]. Chin J Integr Med. 2018;24(10):785\u2013788. doi:10.1007/s11655-018-3012-4", "ArticleIdList": ["10.1007/s11655-018-3012-4", "30267370"]}, {"Citation": "Yang N, Sun RB, Zhao YQ, et al. High fat diet aggravates the nephrotoxicity of berberrubine byinfluencingon its pharmacokinetic profile. Environ Toxicol Pharmacol. 2016;46:319\u2013327. doi:10.1016/j.etap.2016.08.003", "ArticleIdList": ["10.1016/j.etap.2016.08.003", "27525563"]}, {"Citation": "Jin X, Yan TH, Yan Y, et al. Design, synthesis, and anticancer activity of novel berberine derivatives prepared via CuaaC \u201cclick\u201d chemistry as potential anticancer agents. Drug Des Devel Ther. 2014;8:1047\u20131059. doi:10.2147/DDDT.S63228", "ArticleIdList": ["10.2147/DDDT.S63228", "PMC4128789", "25120353"]}, {"Citation": "Wang K, Li WW, Chen JM, et al. Detection of cysteine- and lysine-based protein adductions by reactive metabolites of 2,5-dimethylfuran. Anal Chim Acta. 2015;896:93\u2013101. doi:10.1016/j.aca.2015.09.017", "ArticleIdList": ["10.1016/j.aca.2015.09.017", "26481992"]}, {"Citation": "Wang XQ, Wang SH, Ma JS, et al. Pharmacokinetics in rats and tissue distribution in mouse of berberrubine by UPLC-MS/MS. J Pharm Biomed Anal. 2015;115:368\u2013374. doi:10.1016/j.jpba.2015.07.031", "ArticleIdList": ["10.1016/j.jpba.2015.07.031", "26279368"]}, {"Citation": "Wang K, Chai LW, Feng XC, et al. Metabolites identification of berberine in rats using ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry[J]. J Pharm Biomed Anal. 2017;139:73\u201386. doi:10.1016/j.jpba.2017.02.038", "ArticleIdList": ["10.1016/j.jpba.2017.02.038", "28279930"]}, {"Citation": "Tan XS, Ma JY, Feng R, et al. Tissue Distribution of Berberine and Its Metabolites after Oral Administration in Rats[J]. PLoS One. 2013;8.", "ArticleIdList": ["PMC3815028", "24205048"]}, {"Citation": "Singh N, Sharma B. Toxicological Effects of Berberine and Sanguinarine[J]. Front Mol Biosci. 2018;19:5\u201321.", "ArticleIdList": ["PMC5867333", "29616225"]}, {"Citation": "K\u0119pka A, Zwierz P, Chojnowska S, et al. Relation of plasma carnitine and aminotransferases to alcohol dose and time of dependence[J]. Alcohol. 2019;81:62\u201369. doi:10.1016/j.alcohol.2019.04.004", "ArticleIdList": ["10.1016/j.alcohol.2019.04.004", "31029632"]}, {"Citation": "Pol S, Nalpas B, Vassault A, et al. Hepatic activity and mRNA expression of aspartate aminotransferase isoenzymes in alcoholic and nonalcoholic liver disease[J]. Hepatology. 1991;14:620\u2013625.", "ArticleIdList": ["1916663"]}, {"Citation": "McGill MR, Jaeschke J. Animal models of drug-induced liver injury[J]. Biochim Biophys Acta Mol Basis Dis. 2019;1865(5):1031\u20131039. doi:10.1016/j.bbadis.2018.08.037", "ArticleIdList": ["10.1016/j.bbadis.2018.08.037", "PMC6478394", "31007174"]}, {"Citation": "Jaeschke H, Williams CD, Ramachandran A, et al. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity[J]. Liver Int. 2012;32(1):8\u201320. doi:10.1111/j.1478-3231.2011.02501.x", "ArticleIdList": ["10.1111/j.1478-3231.2011.02501.x", "PMC3586825", "21745276"]}, {"Citation": "Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4(6):489\u2013499. doi:10.1038/nrd1750", "ArticleIdList": ["10.1038/nrd1750", "15931258"]}, {"Citation": "Yasemin HB, Ceylan AK, Ufuk KC. Liver immunology and herbal treatment. World J Hepatol. 2017;9(17):757\u2013770. doi:10.4254/wjh.v9.i17.757", "ArticleIdList": ["10.4254/wjh.v9.i17.757", "PMC5474722", "28660010"]}, {"Citation": "Gao B, Jeong WI, Tian ZG. Liver: an organ with predominant innate immunity. Hepatology. 2008;47(2):729\u2013736. doi:10.1002/hep.22034", "ArticleIdList": ["10.1002/hep.22034", "18167066"]}, {"Citation": "Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev. 2004;36(2):301\u2013312. doi:10.1081/DMR-120034148", "ArticleIdList": ["10.1081/DMR-120034148", "15237856"]}, {"Citation": "Wang K, Wang H, Peng Y, et al. Identification of Epoxide-Derived Metabolite(s) of Benzbromarone[J]. Drug Metab Dispos. 2016;44(4):607\u2013615. doi:10.1124/dmd.115.066803", "ArticleIdList": ["10.1124/dmd.115.066803", "26792818"]}, {"Citation": "Wang K, Lin DJ, Guo XC, et al. Chemical Identity of Interaction of Protein with Reactive Metabolite of Diosbulbin B In Vitro and In Vivo[J]. Toxins. 2017;9(8):249\u2013264. doi:10.3390/toxins9080249", "ArticleIdList": ["10.3390/toxins9080249", "PMC5577583", "28805726"]}, {"Citation": "Lan JR, Zhao YY, Dong FX, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69\u201381.", "ArticleIdList": ["25498346"]}, {"Citation": "Ahmed T, Gilani AH, Abdollahi M, et al. Berberine and neurodegeneration: a review of literature. Pharmacol Rep. 2015;67(5):970\u2013979. doi:10.1016/j.pharep.2015.03.002", "ArticleIdList": ["10.1016/j.pharep.2015.03.002", "26398393"]}, {"Citation": "Kaboli PJ, Rahmat A, Ismail P, et al. Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. Eur J Pharmacol. 2014;740:584\u2013595. doi:10.1016/j.ejphar.2014.06.025", "ArticleIdList": ["10.1016/j.ejphar.2014.06.025", "24973693"]}]}], "History": [{"Year": "2020", "Month": "8", "Day": "6"}, {"Year": "2020", "Month": "9", "Day": "26"}, {"Year": "2020", "Month": "10", "Day": "30", "Hour": "5", "Minute": "52"}, {"Year": "2020", "Month": "10", "Day": "31", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "8", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "10", "Day": "22"}], "PublicationStatus": "epublish", "ArticleIdList": ["33122887", "PMC7588839", "10.2147/DDDT.S274627", "274627"]}}]}